Pfizer
Pfizer is a research-based biopharmaceutical company, developing and manufacturing human and veterinary medicines, as well as consumer healthcare products. The Company applies science and its global resources to improve health and well-being at every stage of life. Its diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products, and many consumer health care products. The Company operates in two business segments: biopharmaceutical and diversified. Biopharmaceutical segment includes the primary and specialty care, established products, emerging markets and oncology customer-focused units. Diversified segment offers animal health products that prevent and treat diseases in livestock and companion animals, and consumer healthcare products. Pfizer develops and produces medicines and vaccines for a wide range of conditions including in the areas of immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain.
Pfizer was founded in 1849 and is headquartered in New York, US
Report incorrect company information
Key People/Management at Pfizer
Ian Read
Chairman of the Board and Chief Executive Officer
Doug Lankler
Executive Vice President, General Counsel
Chuck Hill
Executive Vice President, Worldwide Human Resources
Mikael Dolsten
President, Worldwide Research and Development and Executive Vice President of Pfizer Inc
Albert Bourla
Chief Operating Officer, Pfizer
Frank D'Amelio
Executive Vice President, Business Operations and Chief Financial Officer
Report incorrect company information
Pfizer Office Locations
Pfizer has offices in Surrey, Zürich, Sollentuna, Alcobendas and in 36 other locations
New York, US (HQ)
235 E 42nd St
Buenos Aires, AR
Panamericana Collector 1804, 1st Floor - Sector B - South Side
Melrose Park, AU
38-42 Wharf Rd
Wien, AT
1 Floridsdorfer Hauptstraße
Minsk, BY
403 8 praspiekt Dziaržynskaha
Ixelles, BE
17 Boulevard de la Plaine
Report incorrect company information
Pfizer Financials and Metrics
Pfizer Financials
Pfizer's revenue was reported to be $52.82 b in FY, 2016 which is a 8.1% increase from the previous period.
| USD | |
|---|---|
Revenue (Q2, 2017) | 12.9 b |
Market capitalization (23-Apr-2018) | 222.9 b |
Pfizer's current market capitalization is $222.9 b.
- Source: SEC Filings
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 51.6 b | 49.6 b | 48.9 b | 52.8 b |
Revenue growth, % | (4%) | (2%) | 8% | |
Cost of goods sold | 9.6 b | 9.6 b | 9.6 b | 12.3 b |
Gross profit | 42 b | 40 b | 39.2 b | 40.5 b |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q3, 2016 | Q1, 2016 | Q2, 2016 | Q2, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 12.6 b | 11.4 b | 12.8 b | 12.4 b | 10.9 b | 11.9 b | 12.1 b | 12.9 b | |||
Cost of goods sold | 2.3 b | 2 b | 2.5 b | 2.4 b | 1.8 b | ||||||
Gross profit | 10.4 b | 9.3 b | 10.3 b | 10 b | 9 b | ||||||
Gross profit Margin, % | 82% | 82% | 81% | 81% | 83% |
- Source: SEC Filings
Annual
| usd | Y, 2011 | Y, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|---|---|
Cash | 3.2 b | 10.1 b | 2.2 b | 3.3 b | 3.6 b | |
Inventories | 6.2 b | 5.7 b | ||||
Current Assets | 56.2 b | 57.7 b | 43.8 b | 38.9 b | ||
PP&E | 12.4 b | 11.8 b |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q3, 2016 | Q1, 2016 | Q2, 2016 | Q1, 2017 | Q2, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 2.1 b | 2.9 b | 3.4 b | 2.4 b | 3.6 b | 3.7 b | 3.1 b | |||||
Inventories | 6.5 b | 6.1 b | 6.2 b | 6.4 b | 5.8 b | 5.8 b | 7.6 b | 7.6 b | ||||
Current Assets | 59.5 b | 57.8 b | 58.3 b | 57 b | 49.4 b | 51.7 b | 45 b | 38.5 b | 41.3 b | 43.8 b | 35.9 b | 36.4 b |
PP&E | 12.4 b | 12.3 b | 12.2 b | 12 b | 11.5 b | 11.4 b | 13.7 b |
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 22.1 b | 9.2 b | ||
Inventories | (538 m) | 175 m | (199 m) | 365 m |
Accounts Payable | 382 m | 297 m | 254 m | 871 m |
Cash From Operating Activities | 17.8 b | 16.9 b | 14.5 b | 15.9 b |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2017 |
|---|---|---|---|---|---|---|
Net Income | 2.6 b | 2.3 b | 2.9 b | 2.7 b | 2.4 b | |
Depreciation and Amortization | 3.1 b | |||||
Cash From Operating Activities | 4.8 b | |||||
Purchases of PP&E | (806 m) |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 133.6 k |
Financial Leverage | 2.9 x |
Pfizer Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| Medivation | August 22, 2016 | $14 b |
| Anacor Pharmaceuticals | June 24, 2016 | $5.20 b |
| Allergan | November 23, 2015 | $160 b |
Report incorrect company information
Pfizer News and Updates
April 24, 2018
United States Sexually Transmitted Diseases Drug Market: Industry Trends, Share, Size and 2025 Future Report
Sexually Transmitted Diseases Drug Market: Rising Incidence of Sexually Transmitted Diseases Fuels Demand for Effective Drugs.Sexually Transmitted Diseases Drug Market to Reach US$ 83.04 Billion by 2025: Posted via Industry Today. Follow us on Twitter @IndustryToday
April 23, 2018
FDA to Pfizer: To win OK for Herceptin biosimilar, fork over more 'technical' info
U.S. regulators knocked back Pfizer's biosimilar version of Roche's breast cancer stalwart Herceptin, the drug giant's second biosim knockoff to fall short at the FDA. The delay will put Pfizer even farther behind Mylan and Biocon, which nabbed an FDA green light in December.
April 23, 2018
Pfizer's first U.K. ads for OTC Viagra put erectile dysfunction in perspective
Pfizer’s first ad campaign for over-the-counter Viagra in the U.K. uses comparisons to illustrate the relative commonplace incidence of erectile dysfunction. Print and out-of-home ads begin with the fact that “4.3 million men in the U.K. experience erectile problems.” The text-heavy ads then note co…
April 23, 2018
Zolmitriptan Nasal Spray Market Analysis, Market Size, Regional Outlook, Competitive Strategies and Forecasts, 2017 To 2022, Focusing On Top Key Vendors: Pfizer, Bayer, AptarGroup, Merck, Sanofi
The Global Zolmitriptan Nasal Spray Market Report includes a comprehensive analysis of the present market. The report starts with the basic Zolmitriptan Nasal Spray Market overview and then goes into each and every detail. Posted via Industry Today. Follow us on Twitter @IndustryToday
April 20, 2018
Clinical Trial Management System Market Key Developments 2018 | Company Overview with Forte Research Systems, eClinForce, iWEb Technologies and more.
Latest research study from Market Research Future with title Global Clinical trial management system Market by Manufacturers, Regions, Type and Application, Forecast to 2023. The Research report presents a complete assessment of the market and contains Future trend and Current Growth Factors. Posted…
April 19, 2018
Generic Injectable Market Analysis and Forecast by Future Market Insights
Generic Injectable Market Analysis and Forecast by Future Market Insights Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information